Company

Primrose Bio, Inc.

Primrose Bio develops strain engineering and protein production technologies for therapeutics and vaccines.

About

Primrose Bio develops strain engineering and protein production technologies for therapeutics and vaccines targeting cancer and infectious diseases. Its platforms include Pfenex Expression Technology®, Prima RNApols™, and PeliCRM197®, as well as commercialized products such as Rylaze®. Formed in 2023 through the merger of Pelican Technology Holdings and Primordial Genetics, the company is based in San Diego, US. In September 2026, it raised venture funding led by Signet Healthcare Partners, with participation from 1315 Capital, Ligand Pharmaceuticals, Inc., LDV Management, and Agent Capital.

2Funding rounds

5Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in